SHIONOGI & CO., LTD.

Shionogi Announces Initial Data from Phase IIb study of S-555739, Prostaglandin D2 Receptor Antagonist

Osaka, Japan, June 14, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi" or "the Company") today announced initial data from domestic phase IIb study of S-555739, prostaglandin D2 (PGD2) receptor antagonist created by the Company. In the phase IIb study, Shionogi confirmed that combination therapy with antihistamine reproducibly showed significant effect compared with antihistamine alone in co-primary endpoints: changes from baseline of three nasal symptoms of allergic rhinitis.

S-555739 shows a potent PGD2 receptor antagonist activity. Mono-therapy and combination therapy with antihistamine showed suppressive effects against symptoms of allergic rhinitis in the phase IIa study in Japan. From the results of phase IIb study, Shionogi has decided to start phase IIa study in the US as part of the global development of S-555739.

Shionogi strives to provide a new treatment option for a lot of patients in the world still suffering from symptoms of allergic rhinitis by developing S-555739 which has a new mechanism of action.

About S-555739

S-555739 is a PGD2 receptor antagonist created by Shionogi. PGD2 is a kind of endogenous biologically active agent secreted from mast cells, and is involved in allergy or inflammatory responses. S-555739 is expected to show suppressive effect against symptoms of allergic rhinitis by inhibiting the PGD2 receptor. S-555739 is orally administered once daily and shows good tolerability.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596